Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Interferon lambda-containing aerosol inhalant

A technology of aerosol inhalation and interferon, which can be used in aerosol delivery, antiviral agents, respiratory diseases, etc., and can solve the problems of late discovery and reporting of type III interferon.

Inactive Publication Date: 2016-08-17
BEIJING TRI PRIME GENE PHARMA CO LTD
View PDF10 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Compared with type I and type II interferon, type III interferon was discovered and reported later

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Interferon lambda-containing aerosol inhalant
  • Interferon lambda-containing aerosol inhalant
  • Interferon lambda-containing aerosol inhalant

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Embodiment 1: the preparation of interferon atomized inhalation

[0041] The nebulized inhalation of interferon was prepared according to the method in Table 1 below. Wherein "PB" is disodium hydrogen phosphate-sodium dihydrogen phosphate buffer solution (pH7.0).

[0042] Table 1 Preparation of interferon aerosol inhalation

[0043]

[0044]

[0045]

[0046]

Embodiment 2

[0047] Embodiment 2: the animal test of interferon atomized inhalation treatment viral pneumonia

[0048] 1) RSV virus culture

[0049] The RSV standard strain RSV-Long (quoted from the Beijing Institute of Pediatrics) was inoculated on Hep-2 cells, harvested when the cytopathic rate reached more than 80%, and the virus liquid was frozen in liquid nitrogen and stored at 37°C Melt, centrifuge at 1000rpm for 10 minutes, and take the supernatant for later use.

[0050] 2) Establishment of RSV mouse infection model

[0051] Take 126 6-7-week-old Balb / c mice, half male and half male, all anesthetized with ether, and instill 10 6 PFU / ml RSV virus liquid 0.1ml, instill the virus once a day, a total of 2 infusions, on the 3rd day, the mice showed positive reactions such as piloerection, restlessness, shortness of breath, and abdominal muscle convulsions, indicating that the RSV infection mouse model was successfully established.

[0052] 3) Grouping and administration

[0053] The...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of preparations of biotechnology medicines, and relates to an interferon lambda-containing aerosol inhalant. The aerosol inhalant contains 1-1000 micrograms of interferon lambda and a right amount of pharmaceutical adjuvant of the aerosol inhalant in a single dosage of administration; preferentially, the aerosol inhalant contains 5-100 micrograms of interferon lambda and a right amount of pharmaceutical adjuvant of the aerosol inhalant in a single dosage of administration; more preferentially, the aerosol inhalant contains 10-50 micrograms of interferon lambda and a right amount of pharmaceutical adjuvant of the aerosol inhalant in a single dosage of administration. Compared with the traditional interferon alpha-containing aerosol inhalant, the interferon lambda-containing aerosol inhalant obviously improves the treatment effect when being used for treating viral pneumonia.

Description

technical field [0001] The present invention generally relates to the respiratory tract and pulmonary administration preparations of interferon, and particularly relates to the nebulized inhalation preparation of interferon. Background technique [0002] Viral pneumonia is a common disease in infants and young children, which seriously endangers the life and health of infants and young children. According to incomplete statistics, more than 90% of infants and young children have been infected with viral pneumonia before the age of 2, of which more than 80% of the cases are within 1 year old, the peak age of onset is 2-6 months, and severe cases can be seen in 1-6 months . The death rate of infants and young children caused by infection of viral pneumonia is 0.5%-2.0% in developed countries, up to 7% in developing countries, and it is the leading cause of infant death in my country. In addition, viral pneumonia is very contagious and reinfectious. It has been reported that ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/21A61K9/12A61P31/12A61P11/00
CPCA61K38/21A61K9/12A61K47/42
Inventor 周敏毅刘金毅程永庆
Owner BEIJING TRI PRIME GENE PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com